Back to Journals » Transplant Research and Risk Management » Volume 2

Clinical use of plerixafor in combination with granulocyte-colony stimulating factor in hematopoietic stem cell transplantation

Authors Fowler C, Mariarz R

Published 11 May 2010 Volume 2010:2 Pages 47—58


Review by Single anonymous peer review

Peer reviewer comments 3

Cedar J Fowler1, Richard T Maziarz2

1Laboratory of Clinical Infectious Diseases – NIAID, National Institutes of Health, Bethesda, MD, USA; 2Adult Blood and Marrow Stem Cell Transplant Program, Oregon Health and Science University, Portland, OR, USA

Abstract: Plerixafor is a CXC4:CXCL12 antagonist that has an expanding role in the stem cell mobilization phase of the hematopoietic stem cell transplant procedure. The drug is currently licensed by the FDA to be used in combination with granulocyte colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells into the peripheral blood for collection and subsequent autologous transplantations in patients with non-Hodgkin’s lymphoma and multiple myeloma. Plerixafor is particularly useful in patients who have been heavily pretreated or as effective therapy for frontline salvage of poor peripheral blood stem cells mobilizers. In conjunction with G-CSF, plerixafor can be successful in decreasing the number of apheresis days and therefore the associated additional risks and cost of more apheresis procedures. Patients taking plerixafor, when compared to the side effect profile of G-CSF alone, do not report significantly more side effects.

Keywords: plerixafor, AMD3100, autologous stem cell mobilization, non-Hodgkin’s lymphoma, multiple myeloma, CXCR4, CXCL12

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.